The Chicago Entrepreneur

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs 

The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into key drug brands and research and development programs.

Previous post Paris Olympics is the latest test of whether sports can win subscribers for NBC’s Peacock
Next post IGT and Everi rally on $6.3 billion acquisition deal with Apollo